Trial Profile
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors GW Pharmaceuticals
- 24 Feb 2021 Results published in the British Journal of Cancer
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 10 Aug 2016 Data expected in 4Q of 2016, as per GW Pharmaceuticals media release.